Alexander Whelan1, Mary Halpine1, Sean D Christie2, Sonja A McVeigh1. 1. Division of Physical Medicine and Rehabilitation, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 2. Department of Surgery (Neurosurgery), Dalhousie University, Halifax, Nova Scotia, Canada.
Abstract
Context: Pineal melatonin production is mediated by afferent signaling pathways that navigate through the cervicothoracic spinal cord. Melatonin profiles in individuals with complete cervical spinal cord injury (SCI) have not been systematically reviewed despite this proposed pathway. Objectives: The primary objective was to understand melatonin profiles in individuals with complete cervical SCI, as compared to healthy controls and those with thoracolumbar and incomplete cervical SCI. Secondary objectives were to understand the impact of injury chronicity and melatonin supplementation on melatonin values in adults with complete cervical SCI. Methods: This review (PROSPERO ID: CRD42017073767) searched several databases and gray literature sources from January 1978 to August 2017. Studies were eligible if they evaluated melatonin levels (blood, saliva or urinary metabolite measurements) in adults with complete cervical SCI. 390 studies were screened and 12 studies met final selection criteria. Given the heterogeneity in study designs, a narrative analysis was performed. Results: There is evidence that adults with complete cervical SCI have absent diurnal melatonin rhythms as compared to healthy controls and individuals with thoracolumbar SCI below T3. There is limited evidence comparing levels in individuals with incomplete tetraplegia. There is insufficient evidence describing profiles immediately (<2 weeks) after cervical SCI. Based on a limited number of studies, melatonin supplementation does not appear to improve sleep outcomes in adults with long-standing complete cervical SCI. Conclusions: Future research should explore melatonin levels acutely after cervical SCI and the impact of supplementation on non-sleep outcomes.
Context: Pineal melatonin production is mediated by afferent signaling pathways that navigate through the cervicothoracic spinal cord. Melatonin profiles in individuals with complete cervical spinal cord injury (SCI) have not been systematically reviewed despite this proposed pathway. Objectives: The primary objective was to understand melatonin profiles in individuals with complete cervical SCI, as compared to healthy controls and those with thoracolumbar and incomplete cervical SCI. Secondary objectives were to understand the impact of injury chronicity and melatonin supplementation on melatonin values in adults with complete cervical SCI. Methods: This review (PROSPERO ID: CRD42017073767) searched several databases and gray literature sources from January 1978 to August 2017. Studies were eligible if they evaluated melatonin levels (blood, saliva or urinary metabolite measurements) in adults with complete cervical SCI. 390 studies were screened and 12 studies met final selection criteria. Given the heterogeneity in study designs, a narrative analysis was performed. Results: There is evidence that adults with complete cervical SCI have absent diurnal melatonin rhythms as compared to healthy controls and individuals with thoracolumbar SCI below T3. There is limited evidence comparing levels in individuals with incomplete tetraplegia. There is insufficient evidence describing profiles immediately (<2 weeks) after cervical SCI. Based on a limited number of studies, melatonin supplementation does not appear to improve sleep outcomes in adults with long-standing complete cervical SCI. Conclusions: Future research should explore melatonin levels acutely after cervical SCI and the impact of supplementation on non-sleep outcomes.
Authors: K Stoschitzky; A Sakotnik; P Lercher; R Zweiker; R Maier; P Liebmann; W Lindner Journal: Eur J Clin Pharmacol Date: 1999-04 Impact factor: 2.953
Authors: G Citera; M A Arias; J A Maldonado-Cocco; M A Lázaro; M G Rosemffet; L I Brusco; E J Scheines; D P Cardinalli Journal: Clin Rheumatol Date: 2000 Impact factor: 2.980
Authors: Susan Benloucif; Helen J Burgess; Elizabeth B Klerman; Alfred J Lewy; Benita Middleton; Patricia J Murphy; Barbara L Parry; Victoria L Revell Journal: J Clin Sleep Med Date: 2008-02-15 Impact factor: 4.062
Authors: Helen Slawik; Michael Stoffel; Lina Riedl; Zdenko Veselý; Michael Behr; Jens Lehmberg; Corina Pohl; Bernhard Meyer; Michael Wiegand; Sandro M Krieg Journal: J Biol Rhythms Date: 2015-12-07 Impact factor: 3.182
Authors: Andre Leite Gonçalves; Adriana Martini Ferreira; Reinaldo Teixeira Ribeiro; Eliova Zukerman; José Cipolla-Neto; Mario Fernando Prieto Peres Journal: J Neurol Neurosurg Psychiatry Date: 2016-05-10 Impact factor: 10.154